直接口服抗凝药在老年房颤患者中的药代与药效学见解:结构化叙述综述
老年人DOAC暴露个体间变异大,与肾功能、体成分变化及P-gp抑制剂联用相关;达比加群变异最大且仅以年龄为剂量调整标准,非优选。暴露超出治疗范围与卒中和出血事件显著相关,但尚无明确阈值。
要点
- 老年人DOAC暴露个体间变异大,与肾功能、体成分及P-gp抑制剂联用相关。
- 达比加群个体间变异最大且仅以年龄调整剂量,非老年优选。
- 暴露超出治疗范围与卒中和出血事件显著相关,但无明确阈值。
核心结论
- 老年人DOAC暴露个体间变异大,与肾功能、体成分变化及P-gp抑制剂联用相关。
- 达比加群个体间变异最大且仅以年龄为剂量调整标准,非优选。
- DOAC暴露超出治疗范围与卒中和出血事件显著相关,但尚无明确阈值。
研究设计与样本
- 纳入药物为阿哌沙班、达比加群、依度沙班和利伐沙班。
主要发现
- 年龄本身不影响依度沙班、利伐沙班和达比加群的暴露。
- 阿哌沙班峰浓度在老年人中比年轻志愿者高40%。
- 老年人DOAC暴露个体间变异大,与肾功能、体成分变化及P-gp抑制剂联用相关。
- 达比加群个体间变异最大,因其剂量调整标准仅基于年龄。
- DOAC暴露超出治疗范围与卒中和出血事件显著相关。
关键数值与推荐
- 阿哌沙班峰浓度在老年人中比年轻志愿者高40%。
- 达比加群剂量调整标准仅基于年龄。
- 阿哌沙班、依度沙班和利伐沙班的剂量减少标准与肾功能、体成分变化及P-gp抑制剂联用一致。
临床怎么用
- 老年房颤患者使用DOAC需关注肾功能、体成分变化及P-gp抑制剂联用对暴露的影响。
- 达比加群因个体间变异大且仅以年龄调整剂量,老年患者非优选。
局限性
- 尚无明确与卒中和出血事件相关的DOAC暴露阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Older adults, the fastest growing population, represent almost 50% of all users of direct oral anticoagulants (DOACs). Unfortunately, we have very little relevant pharmacological and clinical data on DOACs, especially in older adults with geriatric profiles. This is highly relevant as pharmacokinetics and pharmacodynamics (PK/PD) often differ substantially in this population. Hence, we need to obtain a better understanding of the PK/PD of DOACs in older adults, to ensure appropriate treatment. This review summarises the current insights into PK/PD of DOACs in older adults. A search was undertaken up to October 2022 to identify PK/PD studies of apixaban, dabigatran, edoxaban, and rivaroxaban, that included older adults aged ≥ 75 years. This review identified 44 articles. Older age alone did not influence exposure of edoxaban, rivaroxaban and dabigatran, while apixaban peak concentrations were 40% higher in older adults than in young volunteers. Nevertheless, high interindividual variability in DOAC exposure in older adults was noted, which can be explained by distinctive older patient characteristics, such as kidney function, changes in body composition (especially reduced muscle mass), and co-medication with P-gp inhibitors, which is in line with the current dosing reduction criteria of apixaban, edoxaban, and rivaroxaban. Dabigatran had the largest interindividual variability among all DOACs since its dose adjustment criterion is only age, and thus it is not a preferable option. Additionally, DOAC exposure, which fell outside of on-therapy ranges, was significantly related to stroke and bleeding events. No definite thresholds linked to these outcomes in older adults have been established.
引用
- Edwina AE, Dia N, Dreesen E, et al. Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review. Clin Pharmacokinet. 2023. PMID: 36862336. doi:10.1007/s40262-023-01222-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。